Clinical studies

Prof. Dr. med. S. Petri

Staff members:

Prof. Dr. med. K. Kollewe, functional senior physician, specialist in neurology

Prof. Dr. med. Sonja Körner, senior consultant, specialist in neurology

Dr. med. Claas Janssen, specialist in neurology

Dr. med. Olivia Schreiber-Katz, specialist in neurology

Dr. med. Alma Osmanovic, assistant physician

Dr. med. Anastasia Sarikidi, assistant physician

Dr. med. Lars Müschen, assistant physician

Iraima Cespedes, assistant physician

Chantal Fischer, study coordinator

 

 

The following studies on new therapies for neuromuscular diseases are currently underway at the Clinical Department of Neurology:

 

Amyotrophic lateral sclerosis (ALS):

 

  • ROCK-ALS: a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

The study investigates the efficacy and tolerability of the substance Fasudil as well as the effect on the course of ALS disease. Fasudil is an inhibitor of the enzyme Rho-kinase (called ROCK), which is supposed to inhibit the destruction of motor nerve cells by stabilizing the cytoskeleton (cell framework).

ClinicalTrials.gov Identifier: NCT03792490

 

  • REFALS: Effects of oral levosimendan (OMD-109) on respiratory function in patients with ALS. Levosimendan increases the performance of weakened muscles by activating troponin, has anti-inflammatory properties and can reduce the deposition of proteins (protein aggregation) in nerve cells in ALS.

ClinicalTrials.gov Identifier: NCT03505021

 

  • ORARIALS-01: A Phase III, Randomized, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis. Arimoclomol is a chaperone activator designed to delay the pathological deposition of specific proteins (protein aggregation of TDP-43, SOD-1 and FUS) in motor neurons.

ClinicalTrials.gov Identifier: NCT03491462

Post-polio syndrome:

  • Multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous immunoglobulin (flebogamma 5% DIF) in patients with post-polio syndrome (FORCE)

ClinicalTrials.gov Identifier: NCT02176863

 

Contact:

Prof. Dr. med. Susanne Petri

Senior Physician

Clinical Department of Neurology

Hannover Medical School

Carl-Neuberg-Str. 1

30625 Hanover

Phone: 0511 - 532 3740

Fax: 0511 - 532 3115

E-Mail: Petri.Susanne@MH-Hannover.de